₹235.15
Above FV▼ -58.5% against the close used
Model range ₹66.34 – ₹308.76
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Bear₹66.34Fair value₹235.15Bull₹308.76
FairClose
52-week traded range
52W low ₹373.5052W high ₹602.50
The 52-week range is measured from the stored price history, not estimated.
Trading above the consensus fair value
Zydus Wellness Limited closed at ₹566.30, 140.8% above the consensus fair value of ₹235.15 drawn from 9 valuation models.
Financial DNA score 30/100 — Weak. P/E of 79.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
DCF Valuation
₹80.65
-85.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹171.37
-69.7%
√(22.5 × EPS × BVPS)
EPS=6.2, BVPS=210.52 · outside Graham range (P/E 79.3, P/B 2.7) — asset-light, treat as a rough floor
Graham Formula
₹172.14
-69.6%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=10.7%, FD=7%
P/E Fair Value
₹308.76
-45.5%
EPS × 49.8x (sector P/E)
EPS=6.2, Sector P/E=49.8x
Peter Lynch (PEG)
₹66.34
-88.3%
EPS × Growth% (PEG = 1 is fair)
EPS=6.2, g=10.7%
EV/EBITDA
₹221.91
-60.8%
(EBITDA × 15.4x − Net Debt) ÷ Shares
EBITDA=6.57B
Book Value (P/B)
₹83.79
-85.2%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=210.52, ROE=4%, g=6%, r=10%
Reverse DCF
₹566.30
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 27.9% | Historical: 10.7%
Margin of Safety
₹137.42
-75.7%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=183.23, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.